 Home > Active Ingredient News > Drugs Articles > Pfizer's third-generation ALK inhibitor lorlatinib approved in China for the treatment of non-small cell lung cancer

Pfizer's third-generation ALK inhibitor lorlatinib approved in China for the treatment of non-small cell lung cancer

 Last Update: 2022-05-29
 Source: Internet
 Author: User

Tags

rate analysis

2 1 4 mm

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 29, the NMPA official website announced that Pfizer’s lorlatinib tablets have been approved in China for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

Lorlatinib is a third-generation ALK inhibitor that has shown high activity in preclinical lung cancer models harboring ALK rearrangements

In April 2017, Lorlatinib was granted Breakthrough Drug Designation by the FDA for ALK-positive, metastatic NSCLC that has previously received one or more ALK inhibitors and has progressed after treatment

In October 2017, Pfizer announced the complete data of the phase II clinical trial of Lorlatinib, which showed that the drug showed clinically meaningful activity in the treatment of lung tumors and brain metastases in patients with ALK-positive and ROS1-positive advanced NSCLC

In April, Pfizer also announced the latest results of the Phase 3 CROWN trial at the 2022 AACR Annual Meeting

Lung cancer is the leading cause of death from cancer worldwide, and NSCLC accounts for approximately 80-85% of lung cancers

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Best price Pure Tirzepatide powder 10mg vial Tirzepatide CAS 2023788-19-2 ouda

CAS No.: 2023788-19-2

Pharmacy Grade

$40.00/G FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

RU 58841 CAS 154992-24-2 RU58841 Powder Bulk RU-58841 For Hair Growth and Anti Hair Loss

CAS No.: 154992-24-2

Pharmacy Grade

$1-1.2/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.